A-623 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	2

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01305746 (ClinicalTrials.gov)	April 2011	25/2/2011	A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321	An Open-Label Long-term Safety Extension Trial for Subjects With Systemic Lupus Erythematosus Who Ha ...	Systemic Lupus Erythematosus	Drug: A-623	Anthera Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	382	Phase 2	United States;Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan
2	NCT01162681 (ClinicalTrials.gov)	July 2010	13/7/2010	PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subject ...	A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 62 ...	Systemic Lupus Erythematosus	Drug: A-623;Other: Placebo Comparator	Anthera Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	547	Phase 2	United States;Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan

First Previous1Next Last